Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111253 | 0.91 | CHRNB4 (0.47) | KRASHTR2CHTR2AHTR2BCHRNB4 | |
| SCHEMBL7055867 | 0.84 | CHRNB4 (0.53) | KRASCHRNB4CHRNA3CHRNB1CHRNB2 | |
| SCHEMBL906007 | 0.84 | CHRNB4 (0.53) | KRASCHRNB4CHRNA3CHRNB1CHRNB2 | |
| Trifluoroacetic Acid SCHEMBL3121822 | 0.83 | CHRNA3 (0.41) | KRASHTR2CHTR2ACHRNB4CHRNA3 | |
| SCHEMBL4320148 | 0.79 | HTR2C (0.53) | HTR2CHTR2AHTR2B | |
| SCHEMBL4308400 | 0.79 | HTR2C (0.53) | HTR2CHTR2AHTR2B | |
| SCHEMBL4317284 | 0.79 | HTR2C (0.53) | HTR2CHTR2AHTR2B | |
| Trifluoroacetic Acid SCHEMBL3114765 | 0.78 | CHRNA3 (0.46) | KRASHTR2CHTR2ACHRNB4CHRNA3 | |
| SCHEMBL4313298 | 0.76 | HTR2C (0.39) | HTR2CHTR2AHTR2BCHRNB2CHRNA4 | |
| SCHEMBL2641453 | 0.76 | CHRNA7 (0.44) | HTR2CCHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226925-B2 | Compounds, their use and preparation | BIOVITRUM AB (SE) | 2007-06-05 | — | — | US | disclosed |
| US-20040029888-A1 | Novel compounds, their use and preparation | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029888-A1 | Novel compounds, their use and preparation | TPH1, TPH2, HTR1A | KRAS 4604/4885HTR2C 7/4885HTR2A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.